Saturday 17 October 2026
Export PHAT’s income statement to Excel — free account
Phathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024. In the quarter to June 2026, revenue grew 88.0%, EPS grew 80.0%, free cash flow grew 96.9% and total debt fell 19.8%, each against the same quarter a year earlier.
6.92
0.58
−7.73%
Follow PHAT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
6.91 | 9.28 | 0.00 | — | — | — | — | — | — |
Altman Z-Score |
(7.89) | (5.59) | (2.86) | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(21.03) | (11.48) | (4.50) | — | — | — | — | — | — |
Beneish M-Score |
(1.39) | 67.35 | — | — | — | — | — | — | — |
P/Operating CF |
(241.90) | (8.08) | (10.74) | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Sales |
7.42 | 7.74 | 0.00 | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
(7.79) | (1.60) | (1.72) | — | — | — | — | — | — |
EV/FCF |
(7.78) | (1.60) | (1.70) | — | — | — | — | — | — |
Quick Ratio |
1.58 | 3.92 | 9.88 | 5.92 | 9.69 | 5.18 | 65.04 | 0.40 | — |
Current Ratio |
1.73 | 4.20 | 10.25 | 6.12 | 9.86 | 5.25 | 68.20 | 0.41 | — |
Net Debt/EBITDA |
(0.51) | 0.35 | 1.48 | 0.35 | 0.71 | 1.94 | 2.09 | (0.87) | — |
Debt/Assets |
80.68% | 53.24% | 33.31% | 57.80% | 47.34% | 15.92% | 8.92% | 216.19% | 0.00% |
Debt/Equity |
(0.48) | (0.79) | (1.89) | (1.27) | 1.24 | 0.24 | 0.10 | (1.52) | — |
Asset Turnover |
0.55 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.75 | 0.80 | 0.68 | 0.74 | 1.03 | 0.54 | 0.14 | 0.79 | — |
Capex/Depreciation |
(0.06) | (0.05) | (0.67) | (0.38) | (0.08) | (0.65) | (60.55) | — | — |
Interest Coverage |
(2.35) | (3.85) | (3.99) | (6.32) | (19.90) | (27.43) | (25.43) | (94.23) | — |
| 63.97% | 204.89% | 273.21% | 14,877.58% | (108.01%) | (61.14%) | (225.11%) | (1.14%) | — | |
| (69.41%) | (84.41%) | (69.68%) | (111.63%) | (59.39%) | (46.74%) | (197.71%) | (285.59%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (931.32%) | 0.00% | — |
Return on Tangible Assets |
(225.78%) | (121.18%) | (55.87%) | (145.94%) | (85.51%) | (54.50%) | (101.12%) | 100.16% | — |
Average Days of Receivables |
162.85 | 256.30 | 876.11 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
18.72% | 61.68% | 7,316.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
159.74% | 526.07% | 17,291.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
16.40% | 43.52% | 6,601.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
(0.39) | (0.53) | (0.19) | — | — | — | — | — | — |
Graham Number |
20.34 | 21.98 | 11.13 | — | — | — | — | — | — |
Earnings Yield |
(18.44%) | (65.89%) | (42.31%) | — | — | — | — | — | — |
Free Cash Flow Yield |
(13.81%) | (52.03%) | (29.60%) | — | — | — | — | — | — |
Revenue per Share |
2.40 | 0.87 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(2.29) | (4.22) | (2.68) | (3.75) | (4.01) | (2.10) | (3.21) | (0.17) | — |
Capex per Share |
0.00 | 0.00 | (0.03) | (0.03) | (0.01) | (0.03) | (2.22) | 0.00 | — |
Free Cash Flow per Share |
(2.29) | (4.22) | (2.71) | (3.77) | (4.02) | (2.13) | (5.43) | (0.17) | — |
Cash per Share |
1.78 | 4.71 | 7.44 | 3.97 | 4.95 | 8.65 | 21.45 | 0.15 | — |
Shareholders Equity per Share |
(6.01) | (4.01) | (1.42) | (1.91) | 1.95 | 5.85 | 20.05 | (0.21) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(6.01) | (4.01) | (1.42) | (1.91) | 1.95 | 5.85 | 20.05 | (0.21) | — |
Free Cash Flow |
(167.00) | (266.90) | (139.21) | (147.57) | (148.78) | (70.73) | (61.76) | (1.02) | — |
Working Capital |
96.93 | 274.41 | 358.65 | 134.28 | 167.61 | 235.84 | 251.85 | (1.29) | — |
Capital Expenditures |
(0.23) | (0.13) | (1.63) | (1.04) | (0.33) | (1.04) | (25.25) | — | — |
Net Current Asset Value |
(468.35) | (271.76) | (89.17) | (79.11) | 69.25 | 190.53 | 226.38 | (1.29) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 2.40 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
3.43 | 2.02 | 1.14 | 2.26 | 6.33 | 1.62 | 0.90 | — | — |
Cash ROIC |
168.50% | (108.90%) | (31.18%) | (83.93%) | (43.12%) | (13.38%) | (12.49%) | (66.30%) | — |
Accounts Receivable Turnover |
3.00 | 2.73 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
2.92 | 0.69 | 0.01 | 0.08 | 0.05 | 0.03 | 0.02 | 0.00 | — |
Inventory Turnover |
5.18 | 3.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
80.48 | 481.01 | 27,541.11 | 5,885.33 | 3,607.97 | 20,418.10 | 31,891.88 | 0.00 | — |
Days of Inventory on Hand |
89.12 | 146.86 | 2,640.24 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
58.46 | 20.22 | — | — | — | — | — | — | — |
Average Payables |
7.75 | 11.55 | 11.30 | 7.57 | 10.97 | 8.74 | 0.38 | 0.38 | — |
Average Inventory |
4.36 | 2.21 | — | — | — | — | — | — | — |
Average Assets |
318.73 | 396.08 | 289.33 | 177.12 | 242.27 | 276.14 | 129.04 | 0.45 | — |
Average Common Equity |
(345.87) | (163.17) | (73.79) | (1.33) | 133.21 | 211.11 | 113.33 | 113.33 | — |
Columns are period end dates